Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9408MR)

This product GTTS-WQ9408MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9408MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5770MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ3827MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-054
GTTS-WQ12257MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ1379MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ5540MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ8060MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ1437MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ2469MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 181
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW